N-(2-bromophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(2-bromophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-amine
• 化学式: C₁₇H₁₂BrN₅
• 分子量: 366.2
• InChiKey: JPCBSLRCEYKXSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS<br/>[FR] PYRAZOLOPYRIMIDINES UTILISES COMME AGENTS ANTI-HEPATITE C
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005047288A1

  公开（公告）日：2005-05-26

  Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6­C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10­membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'­CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.

  式(I)的吡唑啉衍生物，或其药用可接受的盐，被发现对丙型肝炎感染具有活性，其中：R1为C6-C10芳基，5-到10-成员杂芳基，-(C1-C4烷基)-(C6-C10芳基)或-(C1-C4烷基)-(5-到10-成员杂芳基)；R2为C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基基团，该基团可选择地与C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基环融合；X为-NR'-，-NR'-CO-NR''-，-NR'-L，或-NR'-CO-L-，其中R'和R''相同或不同，分别代表氢或C1-C6烷基，L代表C1-C6烷基基团，R1和R2取代基中的芳基，杂芳基，杂环烷基和碳环烷基基团未取代或通过1、2或3个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、氰基、硝基、C6-C10芳基、C3-C6碳环烷基、5-到10-成员杂环烷基、5-到10-成员杂芳基、-NR'-CO2-R''、- R''、-COR'''-NR'-CO-R'''、-CONR'R''、SO2NR'R''、SO2R'''和-O-(CH2)n-R'''取代。